Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) has shared an update.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has significantly increased its use of wealth management products, entering into new structured deposit agreements on 6 January 2026 with Bank of China (BOC) and Bank of Communications (BOCOM). The company subscribed to a new BOC structured deposit of RMB980 million, bringing its total outstanding principal with BOC to RMB1.42 billion, and committed RMB400 million to a new structured deposit with BOCOM. The scale of these investments means the outstanding amounts at both banks exceed the 5% threshold but remain below 25% under Hong Kong Listing Rules, classifying each subscription as a discloseable transaction and triggering reporting and announcement obligations, signaling an active treasury management strategy that may affect the company’s liquidity profile and risk management approach.
The most recent analyst rating on (HK:6990) stock is a Buy with a HK$545.00 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a Hong Kong-listed biopharmaceutical company based in the People’s Republic of China. It operates in the biotech and pharmaceutical industry, focusing on the research, development and commercialization of biopharmaceutical products and related healthcare solutions for domestic and international markets.
Average Trading Volume: 630,391
Technical Sentiment Signal: Buy
Current Market Cap: HK$100.7B
Learn more about 6990 stock on TipRanks’ Stock Analysis page.